Regeneron Pharmaceuticals, Inc. (ETR:RGO)
Germany
· Delayed Price · Currency is EUR 663.00
-7.80 (-1.16%)
At close: Mar 5, 2026
Regeneron Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Operating Revenue | 13,640 | 13,687 | 12,581 | 11,808 | 15,791 | Upgrade
|
| Other Revenue | 702.6 | 515 | 536.1 | 365.1 | 281.2 | Upgrade
|
| Revenue | 14,343 | 14,202 | 13,117 | 12,173 | 16,072 | Upgrade
|
| Revenue Growth (YoY) | 0.99% | 8.27% | 7.76% | -24.26% | 89.14% | Upgrade
|
| Cost of Revenue | 7,951 | 7,103 | 6,255 | 5,153 | 5,298 | Upgrade
|
| Gross Profit | 6,392 | 7,100 | 6,862 | 7,020 | 10,774 | Upgrade
|
| Selling, General & Admin | 2,700 | 2,954 | 2,631 | 2,116 | 1,825 | Upgrade
|
| Other Operating Expenses | -10 | - | -2.1 | -89.9 | -45.6 | Upgrade
|
| Operating Expenses | 2,690 | 2,954 | 2,629 | 2,026 | 1,779 | Upgrade
|
| Operating Income | 3,702 | 4,145 | 4,233 | 4,994 | 8,995 | Upgrade
|
| Interest Expense | -43.8 | -55.2 | -73 | -59.4 | -57.3 | Upgrade
|
| Interest & Investment Income | 716.8 | 711.4 | 495.9 | 160.1 | 45.8 | Upgrade
|
| Currency Exchange Gain (Loss) | 2.4 | -0.6 | -0.3 | 50.2 | 0.4 | Upgrade
|
| Other Non Operating Income (Expenses) | 988 | 15.9 | -28.8 | 8.8 | 4 | Upgrade
|
| EBT Excluding Unusual Items | 5,365 | 4,817 | 4,627 | 5,154 | 8,988 | Upgrade
|
| Gain (Loss) on Sale of Investments | -10.6 | 117.7 | -241.6 | -39.8 | 386.1 | Upgrade
|
| Other Unusual Items | - | -53.4 | - | - | - | Upgrade
|
| Pretax Income | 5,231 | 4,780 | 4,199 | 4,859 | 9,326 | Upgrade
|
| Income Tax Expense | 725.8 | 367.3 | 245.7 | 520.4 | 1,251 | Upgrade
|
| Net Income | 4,505 | 4,413 | 3,954 | 4,338 | 8,075 | Upgrade
|
| Net Income to Common | 4,505 | 4,413 | 3,954 | 4,338 | 8,075 | Upgrade
|
| Net Income Growth | 2.09% | 11.61% | -8.87% | -46.28% | 129.86% | Upgrade
|
| Shares Outstanding (Basic) | 105 | 108 | 107 | 107 | 106 | Upgrade
|
| Shares Outstanding (Diluted) | 109 | 115 | 114 | 114 | 112 | Upgrade
|
| Shares Change (YoY) | -5.65% | 1.23% | 0.18% | 1.16% | -2.52% | Upgrade
|
| EPS (Basic) | 43.07 | 40.90 | 37.05 | 40.51 | 76.40 | Upgrade
|
| EPS (Diluted) | 41.48 | 38.34 | 34.77 | 38.22 | 71.97 | Upgrade
|
| EPS Growth | 8.19% | 10.27% | -9.03% | -46.89% | 135.81% | Upgrade
|
| Free Cash Flow | 4,081 | 3,665 | 3,875 | 4,425 | 6,529 | Upgrade
|
| Free Cash Flow Per Share | 37.57 | 31.84 | 34.08 | 38.98 | 58.19 | Upgrade
|
| Dividend Per Share | 3.520 | - | - | - | - | Upgrade
|
| Gross Margin | 44.57% | 49.99% | 52.32% | 57.67% | 67.04% | Upgrade
|
| Operating Margin | 25.81% | 29.19% | 32.27% | 41.03% | 55.97% | Upgrade
|
| Profit Margin | 31.41% | 31.07% | 30.14% | 35.64% | 50.24% | Upgrade
|
| Free Cash Flow Margin | 28.45% | 25.80% | 29.54% | 36.35% | 40.63% | Upgrade
|
| EBITDA | 4,246 | 4,628 | 4,654 | 5,335 | 9,281 | Upgrade
|
| EBITDA Margin | 29.60% | 32.59% | 35.48% | 43.83% | 57.75% | Upgrade
|
| D&A For EBITDA | 543.7 | 482.9 | 421 | 341.4 | 286.2 | Upgrade
|
| EBIT | 3,702 | 4,145 | 4,233 | 4,994 | 8,995 | Upgrade
|
| EBIT Margin | 25.81% | 29.19% | 32.27% | 41.03% | 55.97% | Upgrade
|
| Effective Tax Rate | 13.88% | 7.68% | 5.85% | 10.71% | 13.41% | Upgrade
|
| Revenue as Reported | 14,343 | 14,202 | 13,117 | 12,173 | 16,072 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.